馃幆 4-year MFS of 95% vs 88% (HR, 0.42; P = .0001): adding darolutamide to ADT and primary or salvage RT cut the risk of metastasis or death in very high-risk localized prostate cancer. Phase 3 DASL-HiCaP data from #ESMO26 馃憞 @mcgillu @niazi_Dr7 @myESMO #pcsm https://hubs.li/Q04Cdwpr0
54 views 路 0 likes 路 0 reposts 路 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSource: OncLive.com 路 x.com